Abstract: A method is described. The method includes obtaining a relationship between a thickness of a contamination layer formed on a mask and an amount of compensation energy to remove the contamination layer, obtaining a first thickness of a first contamination layer formed on the mask from a thickness measuring device, and applying first compensation energy calculated from the relationship to a light directed to the mask.

Abstract: The present invention provides a bottom plate of a resin tank for three-dimensional printing, which is manufactured through the following steps: substrate surface roughening step: treating the upper surface of a transparent substrate by using a plasma, or disposing a composite film on the upper surface of the transparent substrate to form a non-smooth surface structure having pores; substrate surface modification step: sequentially performing an activation treatment and a fluorination treatment on the upper surface of the transparent substrate; and stabilizer filling step: applying a stabilizer to the upper surface of the transparent substrate to fill the stabilizer penetrates into the pores on the upper surface of the transparent substrate. The low surface energy film reduces the adhesion of the hardened photosensitive material, and the stabilizer maintains the structure of the low surface energy film, so that the resin tank bottom plate has both oleophobic and hydrophobic properties.

Abstract: Compounds of formula (I) are described, wherein each of the variable groups is as defined in the specification. Also described are pharmaceutical compositions containing a compound of formula (I), and uses of the compounds and pharmaceutical compositions for inhibiting Nav1.8 voltage-gated sodium channels and treating Nav1.8 mediated diseases, disorders, and conditions, such as pain and pain-associated diseases, disorders, and conditions and cardiovascular diseases, disorders, and conditions, such as atrial fibrillation.

Abstract: The present invention relates to Nav1.8 Inhibitor 2,3-dihydroquinazolin compounds of Formula (X): wherein Y?, X?, B?, R1?, R2?, R3?, R5?, R6?, R7?, and z1 are as defined herein; or pharmaceutically acceptable salts or tautomer forms thereof, corresponding pharmaceutical compositions or formulations, methods or processes of compound preparation, methods, compounds for use in, uses for and/or combination therapies for treating pain and/or pain-related or associated disease(s), disorder(s) or condition(s), respectively.

Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, to processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).